Clinical Trials Logo

Clinical Trial Summary

This is a Phase III, randomised, multicentre, double-blinded study to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney disease (CKD) and high proteinuria.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06087835
Study type Interventional
Source AstraZeneca
Contact AstraZeneca Clinical Study Information Center
Phone 1-877-240-9479
Email information.center@astrazeneca.com
Status Recruiting
Phase Phase 3
Start date November 7, 2023
Completion date June 30, 2027